Closed · HT9425-23-BCRP-TBCCDA-2 · CFDA 12.420 · Discretionary

DoD Breast Cancer, Transformative Breast Cancer Consortium Development Award

Federal grant opportunity posted by Defense Health Agency Contracting Activity - DHACA, cataloged on Grants.gov.

Varies
Award range
Closed
Status
August 8, 2023
Close date
1
Expected awards

The verdict

DoD Breast Cancer, Transformative Breast Cancer Consortium Development Award is a closed discretionary listing from Defense Health Agency Contracting Activity - DHACA that offered Varies by applicant across 1 expected award. Future funding cycles may be published under the same CFDA number. PlainGrants indexes 1,795 other opportunities from Defense Health Agency Contracting Activity - DHACA.

Varies
award range
Closed
application status
1
expected award
12.420
CFDA program

Archived opportunity record

DoD Breast Cancer is closed (last close August 8, 2023). Check the agency catalog for replacement NOFOs. Defense Health Agency Contracting Activity - DHACA still indexes 1,795 other opportunities here.

According to Grants.gov (extract vintage 2026-08-10), this record reflects the officially published listing. See methodology.

Deadline tracker

Application window closed

Closed August 8, 2023

Posted May 2 Closes Aug 8

Est. Total Funding

$160,000

Expected Awards

1

Instrument

Grant

Description

The FY23 Transformative Breast Cancer Consortium Development Award is intended to provide successful applicants the time and resources needed to bring investigators and breast cancer advocates together to establish a consortium framework and conduct preliminary research to support application to a future, full Transformative Breast Cancer Consortium Award (pending availability of funds). This is a development award and is a separate mechanism from the full consortium award. Recipients of the FY23 Transformative Breast Cancer Consortium Development Award are expected to submit an application to compete for the full Transformative Breast Cancer Consortium Award anticipated to be offered in a future fiscal year(s). However, it is not necessary to receive a development award in order to apply for a full consortium award in the future. For FY23, investigators may be named as Consortium Director on an application submitted to either (but not both) of these mechanisms. Detailed information on the FY23 Transformative Breast Cancer Consortium Award is available under a separate program announcement (HT9425-23-BCRP-TBCCA-2).The FY23 Transformative Breast Cancer Consortium Development Award provides support to:· Develop the infrastructure of a multi-institutional research team inclusive of scientists, clinicians, and breast cancer advocates (e.g., building appropriate collaborations, outlining integration, research management, administrative management, and communication plans, and devising an intellectual property plan)· Generate necessary preliminary data to serve as proof of concept or for project integration· Acquire research resources· Develop a framework of necessary statistical analysesBreast cancer consumer advocates must be active participants in the development and execution of the Transformative Breast Cancer Consortium Development Award.

Catch-all / unrestricted eligibility mark · HT9425-23-BCRP-TBCCDA-2

Grants.gov marks DoD Breast Cancer with a catch-all / unrestricted eligibility code (Unrestricted / see official listing). Read the official announcement text for the real applicant filter — the code alone is not a door list. The extract does not mark applicant cost-sharing as required. Instrument: Grant. Funding-activity code maps to Science and Technology / R&D (ST). This eligibility-code string dominates the Defense Health Agency Contracting Activity - DHACA book (1,791 peers, 100% of 1,796).

Code 99
Unrestricted / see official listing

Codes are Grants.gov eligibility category values from the extract vintage 2026-08-10. Confirm the full eligibility statement on the official listing or the Grants.gov eligibility reference.

Official Listing on Grants.gov

View full details, application forms, and submission instructions.

View on Grants.gov

Agency Contact

CDMRP Help Desk Phone: 301-682-5507 Email: help@eBRAP.org

More from Defense Health Agency Contracting Activity - DHACA

Closed Closed September 22, 2026

DoW Neurofibromatosis Synergistic Idea Award

View →
Closed Closed September 22, 2026

DoW Neurofibromatosis Investigator-Initiated Research Award

View →
Closed Closed September 22, 2026

DoW Neurofibromatosis Research Academy – Scholar Award

View →
Closed Closed September 22, 2026

DoW Neurofibromatosis Exploration-Hypothesis Development Award

View →
Open Closes November 18, 2026

DOW Combat Readiness – Medical Research Program Translational Research Award

View →

What to do next

DoD Breast Cancer is closed; use the parent program and agency catalog for the next funding cycle.

  • Browse open federal opportunities in the same category when this listing is closed. Open opportunities
  • Look up CFDA 12.420 across all indexed listings before you commit to this opportunity alone. Eligibility finder
  • Compare award ranges across federal categories before you pick a single CFDA. All categories

Opportunity deadlines and eligibility change on Grants.gov; PlainGrants mirrors the extract and is not the submission system.

Disclaimer: This information is sourced from Grants.gov and SAM.gov and is for informational purposes only. Opportunity details, deadlines, and eligibility requirements change frequently. Always verify current information directly on Grants.gov before applying. PlainGrants is not affiliated with any federal agency.

Read our methodology - how this data is sourced, computed, and verified.

Data sourced from the SAM.gov Assistance Listings and Grants.gov. See our methodology for details. Retrieved and formatted by PlainGrants